Phase 1 Evaluation of PRT2527 Monotherapy and Combination with Zanubrutinib or Venetoclax in Relapsed/Refractory Hematologic Malignancies

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **PRT2527** as monotherapy and in combination with **Zanubrutinib** or **Venetoclax** in participants with relapsed or refractory hematologic malignancies. This is clinically relevant as it aims to determine the potential therapeutic benefits and adverse effects of PRT2527 in treating various hematologic cancers, including **Small Lymphocytic Lymphoma (SLL)**, **Chronic Lymphocytic Leukemia (CLL)**, **Mantle Cell Lymphoma (MCL)**, **Acute Myeloid Leukemia (AML)**, and others. The study focuses on patients who have not responded to or have relapsed after standard treatments, providing insights into alternative therapeutic options for these challenging conditions.

The clinical trial involves a total of **165 participants** diagnosed with various hematological malignancies, including **Chronic Lymphocytic Leukemia (CLL)**, Small Lymphocytic Lymphoma (SLL), and Acute Myeloid Leukemia (AML), among others. The study population comprises both male and female subjects, with an age range that includes adults and older adults. Participants were selected based on their diagnosis of specific conditions such as T-cell lymphoma (TCL) subtypes and Aggressive B-Cell Non-Hodgkin's Lymphoma. The trial also includes individuals with overlapping syndromes like MDS/myeloproliferative neoplasm (MPN) overlap syndrome. The selection process considered the inclusion of a vulnerable population, although specific lifestyle factors such as diet or physical activity were not detailed. The sponsor did not provide information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of **PRT2527** as a monotherapy and in combination with **zanubrutinib** or **venetoclax** in participants with relapsed or refractory hematologic malignancies. The study targets conditions such as **Small Lymphocytic Lymphoma (SLL)**, **Chronic Myelomonocytic Leukemia (CMML)**, **Myelodysplastic Syndrome (MDS)**, **Richter's Syndrome**, **T-cell Lymphoma (TCL) subtypes**, **Aggressive B-Cell Non-Hodgkin's Lymphoma**, **MDS/myeloproliferative neoplasm (MPN) overlap syndrome**, **Mantle Cell Lymphoma (MCL)**, **Chronic Lymphocytic Leukemia (CLL)**, **Acute Myeloid Leukemia (AML)**, and **Marginal Zone Lymphoma (MZL)**. The trial is structured as a Phase 1 study, employing a randomized, double-blind, controlled design to ensure the reliability and validity of the results.

The trial is expected to commence recruitment on July 3, 2023, and is projected to conclude by March 31, 2026. Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Regular follow-up visits will be scheduled to monitor the participants' health, treatment response, and any adverse events. The end-of-study visit will mark the completion of the trial for each participant, where final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected duration of participant involvement will vary depending on individual response and the specific treatment regimen assigned. Participants may be withdrawn from the study early if they experience significant adverse effects, demonstrate disease progression, or choose to withdraw consent. The trial's design and procedures are meticulously crafted to ensure participant safety while gathering critical data to advance the understanding and treatment of these complex hematologic conditions.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. As the trial is in Phase 3, it aims to provide comprehensive data on the effectiveness of the intervention. The trial is scheduled to conclude by March 31, 2026, with recruitment having commenced on July 3, 2023. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies appropriate for its phase to measure and analyze outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, collected at predetermined timepoints throughout the study duration. The analysis will be conducted in accordance with established clinical trial protocols to ensure the reliability and validity of the efficacy data collected.